LoginSignup
Gilead Sciences logo

Gilead Sciences

Stock
Stock
Ticker: GILD
GILD

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Gilead Sciences has so far distributed $1.64 in 2026. The next dividend will be paid on 29.09.2026

$2.645

CHART BY

Frequently asked questions

The market capitalization of Gilead Sciences is $181.54B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Gilead Sciences's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.656. EPS indicates the company's profitability on a per-share basis.
Currently, 30 analysts cover Gilead Sciences's stock, with a consensus target price of $159.76. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Gilead Sciences reported a revenue of $30.54B.
Yes, Gilead Sciences is paying dividends. The next payment is scheduled for 29.09.2026, with an expected amount of .
Gilead Sciences's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $14.67B. EBITDA measures the company's overall financial performance.
Gilead Sciences has a free cash flow of $12.94B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Gilead Sciences employs approximately 17,000 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Gilead Sciences is 1.24B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$181.54B
EPS (TTM) 
-$2.656
Free Float 
1.24B
Revenue (TTM) 
$30.54B
EBITDA (TTM) 
$14.67B
Free Cashflow (TTM) 
$12.94B

Pricing

1D span
$143.68$146.81
52W span
$108.52$157.26

Analyst Ratings

The price target is $159.76 and the stock is covered by 30 analysts.

Buy

23

Hold

6

Sell

1

Information

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Employees
17,000
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
GILD

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin